Therapeutic antibodies are the largest class of biotherapeutics and have been successful in
treating human diseases. However, the design and discovery of antibody drugs remains …

Colorectal cancer represents 10% of all new cancer cases each year and accounts for
almost 10% of all cancer deaths. According to the WHO, by 2040 there will be a 60 …

Background Osteosarcoma (OS) is the most common primary bone tumor in children and
adolescent. Surgery and multidrug chemotherapy are the standard of treatment achieving 60 …

PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy
and safety of anti–PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy …

Lung cancer remains the first cause of cancer-related death despite many therapeutic
innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily …

Currently, immunotherapy based on PD-1/PD-L1 pathway blockade has improved survival
of non-small cell lung cancer (NSCLC) patients. However, differential responses have been …

Simple Summary Immunotherapy stands as a cornerstone in the treatment of advanced lung
cancer patients without an oncogenic driver mutation. This comprehensive review provides …

Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint
inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy …

Objective: This study evaluated the efficacy and safety of the gemcitabine and oxaliplatin
intrathoracic perfusion chemotherapy (IPCGOR) regimen combined with interleukin-2 (IL-2) …

Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely
used in the treatment of multiple cancer types including lung cancer, which is a leading …